8-K Announcements
6Material company update
Apr 23, 2026·SEC
Material company update
Mar 9, 2026·SEC
Material company update
Feb 12, 2026·SEC
West Pharmaceutical Services, Inc.(WST)Earnings, Financials & Key Ratios
WST•NYSE
$356.08
52.4× P/E·Price updated Jul 7, 2026
AboutWest Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.Show more
- Revenue$3.07B+6.3%
- EBITDA$742M-1.1%
- Net Income$494M+0.2%
- EPS (Diluted)6.80+1.6%
- Gross Margin35.89%+3.6%
- EBITDA Margin24.13%-6.9%
- Operating Margin20.09%-2.3%
- Net Margin16.06%-5.7%
- ROE16.85%-4.8%
WST Price & Volume
West Pharmaceutical Services, Inc. (WST) stock price & volume — 10-year historical chart
Loading chart...
Revenue Rebound Validates High Precision Manufacturing Strategy
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Moderate
Financial:Fortress
Cash Flow:Mixed
Primary Risk:High valuation multiple compression
Key Thesis Takeaways
- West Pharmaceutical Services is emerging from a period of inventory-driven volatility, evidenced by a 21.0% year-over-year revenue growth in 2026Q1.
- The company's massive investment in its manufacturing footprint, with net PPE reaching $3.3 billion, positions it to capture long-term demand for biologic and GLP-1 therapies.
- However, investors should monitor the current P/E of 51.60 and the recent decline in the operating cash flow to net income ratio to 0.65, which may indicate near-term pressure on earnings quality.
Verdict Logic
while the 21.0% revenue growth in 2026Q1 signals a robust recovery, the premium valuation of 51.60x TTM P/E warrants caution until cash conversion ratios stabilize above the recent 0.65 level.
WST Growth Metrics
West Pharmaceutical Services, Inc. (WST) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.2%
5 Years7.44%
3 Years2.13%
TTM11.22%
Profit CAGR
10 Years17.84%
5 Years7.36%
3 Years-5.55%
TTM16.16%
EPS CAGR
10 Years17.99%
5 Years8.27%
3 Years-4.18%
TTM17.58%
Return on Capital
10 Years20.19%
5 Years23.34%
3 Years20.05%
Last Year18.41%
WST Recent Earnings
West Pharmaceutical Services, Inc. (WST) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
Apr 23, 2026Metric
Actual
Est
EPS
$2.13+26.8%
$1.68
Rev
$845M+8.3%
$780M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$2.04+11.5%
$1.83
Rev
$805M+1.3%
$795M
Q4 2025
Oct 23, 2025Metric
Actual
Est
EPS
$1.96+16.7%
$1.68
Rev
$804M+2.4%
$786M
Q3 2025
Jul 24, 2025Metric
Actual
Est
EPS
$1.84+21.9%
$1.51
Rev
$766M+5.5%
$726M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 23, 2026 | $2.13vs $1.68+26.8% | $845Mvs $780M+8.3% |
| Q1 2026 | Feb 12, 2026 | $2.04vs $1.83+11.5% | $805Mvs $795M+1.3% |
| Q4 2025 | Oct 23, 2025 | $1.96vs $1.68+16.7% | $804Mvs $786M+2.4% |
| Q3 2025 | Jul 24, 2025 | $1.84vs $1.51+21.9% | $766Mvs $726M+5.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for West Pharmaceutical Services, Inc. (WST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $356.08 | $25.67B | 52.36 | 6.26% | 16.06% | 16.85% | 0.24% | |
| $127.69 | $8.22B | 21.72 | 5.42% | 9.98% | 18.64% | — | |
| $209.29 | $10.02B | 634.21 | 2.49% | -0.63% | -0.78% | — | |
| $10.20 | $6.96B | -13.08 | -3.41% | -8.42% | -9.59% | — | |
| $44.45 | $20.54B | 27.78 | 10.04% | 3.06% | 5.8% | — | |
| $42.15 | $6.21B | 12.29 | -0.61% | 9.43% | 48.39% | — |
Compare WST vs Peers
West Pharmaceutical Services, Inc. (WST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
WST SEC Filings & Documents
West Pharmaceutical Services, Inc. (WST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when WST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
WST Frequently Asked Questions
West Pharmaceutical Services, Inc. (WST) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is West Pharmaceutical Services, Inc.'s revenue?
West Pharmaceutical Services, Inc. (WST) reported $3.22B in revenue for fiscal year 2025. This represents a 602% increase from $458.8M in 1996.
How fast is West Pharmaceutical Services, Inc. growing?
West Pharmaceutical Services, Inc. (WST) grew revenue by 6.3% over the past year. This is steady growth.
Is WST profitable?
Yes, West Pharmaceutical Services, Inc. (WST) is profitable, generating $542.7M in net income for fiscal year 2025 (16.1% net margin).
Dividend & Returns
Does WST pay dividends?
Yes, West Pharmaceutical Services, Inc. (WST) pays a dividend with a yield of 0.24%. This makes it attractive for income-focused investors.
What is WST's return on equity?
West Pharmaceutical Services, Inc. (WST) has a return on equity (ROE) of 16.9%. This is reasonable for most industries.
What is West Pharmaceutical Services, Inc.'s free cash flow?
West Pharmaceutical Services, Inc. (WST) generated $458.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.